Drug recall D-0455-2021
Product
Glyxambi (empagliflozin and linagliptin) Tablets 25 mg/5 mg 30 tablets Rx only NDC 0597-0164-30 Dist. by: Boehringer Ingelheim (BI) Pharmaceuticals, Inc. Ridgefield, CT 06877 USA
Reason for recall
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Lots and codes
3513
Recall details
- Recalling firm
- Cardinal Health Inc., Dublin, OH
- Quantity
- 592 bottles
- Distribution
- FL, GA, SC
- Type
- Voluntary: Firm initiated
- Recall initiated
- March 15, 2021
- Terminated
- June 17, 2024
Related products
- Glyxambi – drug information
- NDC 0597-0164 Glyxambi · Empagliflozin 25 mg/1; Linagliptin 5 mg/1 · Boehringer Ingelheim Pharmaceuticals, Inc.
- NDC 0597-0182 Glyxambi · Empagliflozin 10 mg/1; Linagliptin 5 mg/1 · Boehringer Ingelheim Pharmaceuticals, Inc.